当前位置: X-MOL 学术Int. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
International Journal of Clinical Oncology ( IF 2.4 ) Pub Date : 2019-04-18 , DOI: 10.1007/s10147-019-01451-9
Azusa Hayano 1 , Yasuo Takashima 1 , Ryuya Yamanaka 1
Affiliation  

BACKGROUND Methotrexate (MTX) is used in first-line treatment of primary central nervous system lymphoma (PCNSL), but most cases result in relapse-acquired resistance to MTX. However, only few studies have reported on internal changes and chemotherapies in PCNSL. METHODS In this study, we generated two MTX-resistant PCNSL cell lines, designated MTX-HKBML and MTX-TK, in addition to a MTX-resistant Burkitt lymphoma cell line, designated MTX-RAJI. We examined gene expression changes and drug sensitivity to a proteasome inhibitor, bortezomib, in these cells. RESULTS Cytotoxic tests revealed that the 50% inhibitory concentration for MTX in MTX-HKBML is markedly higher than that in the other two cell lines. Expression of the genes in MTX and folate metabolisms, including gamma-glutamyl hydrolase and dihydrofolate reductase, are upregulated in both MTX-HKBML and MTX-TK, whereas the gene expression of folylpolyglutamate synthetase, thymidylate synthase, and methylenetetrahydrofolate dehydrogenase 1 were upregulated and downregulated in MTX-HKBML and MTX-TK, respectively, on the other hand, bortezomib sensitivity was observed in MTX-TK, as compared with control TK, but not in MTX-HKBML. CONCLUSION These results indicate the cell-type-specific changes downstream of metabolic pathways for MTX and folate, bortezomib sensitivity, and purine and pyrimidine syntheses, in each PCNSL cell line. The MTX-resistant lymphoma cell lines established may be useful for in vitro relapse models for MTX and development of salvage chemotherapy and drug discovery.

中文翻译:

硼替佐米在耐甲氨蝶呤的原发中枢神经系统淋巴瘤细胞中的细胞类型特异性敏感性。

背景甲氨蝶呤(MTX)用于原发性中枢神经系统淋巴瘤(PCNSL)的一线治疗,但大多数情况下会导致复发性获得性对MTX的耐药性。但是,只有很少的研究报道了PCNSL的内部变化和化学疗法。方法在这项研究中,我们产生了两种耐MTX的PCNSL细胞系,分别称为MTX-HKBML和MTX-TK,以及耐MTX的Burkitt淋巴瘤细胞系,即MTX-RAJI。我们检查了这些细胞中基因表达的变化以及对蛋白酶体抑制剂硼替佐米的药物敏感性。结果细胞毒性试验表明,MTX-HKBML对MTX的50%抑制浓度明显高于其他两种细胞系。基因在MTX和叶酸代谢中的表达,包括γ-谷氨酰水解酶和二氢叶酸还原酶,在MTX-HKBML和MTX-TK中均被上调,而叶酰聚谷氨酸合成酶,胸苷酸合酶和亚甲基四氢叶酸脱氢酶1的基因表达分别在MTX-HKBML和MTX-TK中被上调和下调,另一方面,硼替佐米的敏感性为与对照TK相比,在MTX-TK中观察到这一现象,但在MTX-HKBML中则没有。结论这些结果表明每种PCNSL细胞系中MTX和叶酸,硼替佐米敏感性以及嘌呤和嘧啶合成代谢途径下游的细胞类型特异性变化。建立的耐MTX的淋巴瘤细胞系可用于MTX的体外复发模型以及挽救性化疗和药物发现的开发。和MTX-HKBML和MTX-TK中分别上调和下调亚甲基四氢叶酸脱氢酶1,另一方面,与对照TK相比,在MTX-TK中观察到硼替佐米敏感性,而在MTX-HKBML中则没有。结论这些结果表明每种PCNSL细胞系中MTX和叶酸,硼替佐米敏感性以及嘌呤和嘧啶合成代谢途径下游的细胞类型特异性变化。建立的耐MTX的淋巴瘤细胞系可用于MTX的体外复发模型以及挽救性化疗和药物发现的开发。和MTX-HKBML和MTX-TK中分别上调和下调亚甲基四氢叶酸脱氢酶1,另一方面,与对照TK相比,在MTX-TK中观察到硼替佐米敏感性,而在MTX-HKBML中则没有。结论这些结果表明每种PCNSL细胞系中MTX和叶酸,硼替佐米敏感性以及嘌呤和嘧啶合成代谢途径下游的细胞类型特异性变化。建立的耐MTX的淋巴瘤细胞系可用于MTX的体外复发模型以及挽救性化疗和药物发现的开发。结论这些结果表明每种PCNSL细胞系中MTX和叶酸,硼替佐米敏感性以及嘌呤和嘧啶合成代谢途径下游的细胞类型特异性变化。建立的耐MTX的淋巴瘤细胞系可用于MTX的体外复发模型以及挽救性化疗和药物发现的开发。结论这些结果表明每种PCNSL细胞系中MTX和叶酸,硼替佐米敏感性以及嘌呤和嘧啶合成代谢途径下游的细胞类型特异性变化。建立的耐MTX的淋巴瘤细胞系可用于MTX的体外复发模型以及挽救性化疗和药物发现的开发。
更新日期:2019-04-16
down
wechat
bug